211 related articles for article (PubMed ID: 16563943)
1. The obese patient with diabetes mellitus: from research targets to treatment options.
Sharma AM
Am J Med; 2006 May; 119(5 Suppl 1):S17-23. PubMed ID: 16563943
[TBL] [Abstract][Full Text] [Related]
2. The value of current interventions for obesity.
Sharma AM
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S3-9. PubMed ID: 18580864
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
4. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
Cao Z; Cooper ME
Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
[TBL] [Abstract][Full Text] [Related]
6. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.
Chetty VT; Damjanovic S; Gerstein H; Singh N; Yusuf S; Anand SS; Sharma AM
Blood Press; 2014 Feb; 23(1):54-60. PubMed ID: 23731019
[TBL] [Abstract][Full Text] [Related]
8. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
Sharma AM; Janke J; Gorzelniak K; Engeli S; Luft FC
Hypertension; 2002 Nov; 40(5):609-11. PubMed ID: 12411451
[TBL] [Abstract][Full Text] [Related]
10. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
12. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
13. Kidney disease in diabetology: lessons from 2008.
Schernthaner G
Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
[No Abstract] [Full Text] [Related]
14. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
15. [Adipose tissue renin-angiotensin system in obese].
Yasue S; Ebihara K; Nakao K
Nihon Rinsho; 2012 Sep; 70(9):1550-5. PubMed ID: 23012802
[TBL] [Abstract][Full Text] [Related]
16. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus.
McGuire DK; Winterfield JR; Rytlewski JA; Ferrannini E
Diab Vasc Dis Res; 2008 Mar; 5(1):59-66. PubMed ID: 18398815
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
[TBL] [Abstract][Full Text] [Related]
18. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
19. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
Bilous R
Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
[No Abstract] [Full Text] [Related]
20. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
